Immix Biopharma (IMMX) Assets (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Assets data on file, last reported at $95.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 381.68% year-over-year to $95.8 million; the trailing twelve-month figure through Mar 2026 stood at $95.8 million (up 381.68% YoY), and the FY2025 full-year result was $104.8 million, up 356.86% from the prior year.
• Assets retreated to $95.8 million in Q1 2026, from $104.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $104.8 million in Q4 2025 to a low of $13.2 million in Q1 2023.
• A 5-year average of $30.0 million and a median of $20.0 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets slumped 45.78% in 2025 and surged 381.68% in 2026, its largest moves.
• Tracing IMMX's Assets over 5 years: stood at $14.9 million in 2022, then soared by 33.65% to $19.9 million in 2023, then gained by 15.17% to $22.9 million in 2024, then soared by 356.86% to $104.8 million in 2025, then retreated by 8.61% to $95.8 million in 2026.
• Business Quant data shows IMMX's Assets at $95.8 million in Q1 2026, $104.8 million in Q4 2025, and $20.1 million in Q3 2025.